U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815627) titled 'Safety and Efficacy Evaluation of NH002 As a Contrast Agent in Subjects Undergoing Cardiac Echocardiography' on Jan. 21.
Brief Summary: This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Cardiac Diseases
Intervention:
DRUG: NH002 (P...